{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.8","upperLimit":"30.4","value":"24.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"}],"units":"Participants"}],"title":"All treated participants"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.7","upperLimit":"27.3","value":"19.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"}],"units":"Participants"}],"title":"PD-L1 <1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.7","upperLimit":"39.6","value":"30.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"}],"units":"Participants"}],"title":"PD-L1 >= 1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.3","upperLimit":"27.4","value":"20.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"}],"units":"Participants"}],"title":"PD-L1 <5%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.7","upperLimit":"44.9","value":"33.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"}],"units":"Participants"}],"title":"PD-L1 >=5%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"}],"units":"Participants"}],"description":"Investigator-assessed ORR was defined as the percent of participants with a best overall response of confirmed complete response (CR) or partial response (PR). Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD-L1 expression level = Membranous staining in greater than or equal to 5% and greater than or equal to 1% tumor cells.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W","id":"OG000","title":"Nivolumab 3 mg/kg"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From the date of first dose to the date of objectively documented progression or the date of subsequent therapy, whichever occurs first (up to approximately 45 months)","title":"Objective Response Rate (ORR) Per Investigator","type":"SECONDARY","unitOfMeasure":"Percent of Participants"}